Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 1/2018

01-01-2018 | Urogenital

Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate

Authors: T. Ullrich, M. Quentin, A. K. Schmaltz, C. Arsov, C. Rubbert, D. Blondin, R. Rabenalt, P. Albers, G. Antoch, L. Schimmöller

Published in: European Radiology | Issue 1/2018

Login to get access

Abstract

Objectives

To prospectively evaluate the effect of hyoscine butylbromide (HBB) on visualisation of anatomical details and motion-related artefacts in mp-MRI of the prostate at 3.0 Tesla.

Methods

One hundred and three consecutive patients (65 ± 10 years) were included in this trial, powered to demonstrate an improvement of image quality after HBB administration, assessed on a 5-point scale by two blinded readers. All patients received high-spatial resolution axial T2-weighted TSE sequences at 3.0 T without spasmolytic agent, repeated after application of 40 mg HBB and followed by routine mp-MRI. Secondary endpoints were (1) susceptibility to side effects, (2) dependence of spasmolytic effect on patients´ weight, and (3) prostate volume.

Results

In 68% of patients, HBB significantly improved the anatomic score (mean 3.4 ± 0.9 before and 4.4 ± 0.7 after HBB for both readers, p = <0.001). In 67%, HBB significantly enhanced the artefact score (mean 3.2 ± 1 before and 4.2 ± 0.8 after HBB for reader 1, p = <0.001; 3.2 ± 1 and 4.1 ± 0.8 for reader 2, p = <0.001). Subgroup analysis revealed no statistically significant difference between patients with different bodyweight or prostate volume. Inter-reader agreement was excellent (k = 0.95–0.98).

Conclusions

Hyoscine butylbromide significantly improves image quality and reduces motion-related artefacts in mp-MRI of the prostate independent of bodyweight or prostate volume. No side effects were reported.

Key Points

• Hyoscine butylbromide (HBB) improved image quality in over 2/3 of patients.
• Severe artefacts were reduced after HBB in more than 20%.
• The number of non-diagnostic MRI was reduced to <1% after HBB.
• HBB effect was independent of bodyweight and prostate volume.
• No side effects of HBB were reported in this study population.
Literature
1.
Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRefPubMed
2.
Murphy G, Haider M, Ghai S, Sreeharsha B (2013) The expanding role of MRI in prostate cancer. Am J Roentgenol 201:1229–1238CrossRef
3.
Schimmöller L, Quentin M, Arsov C et al (2014) Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy. Eur J Radiol 12:2103–2108CrossRef
4.
Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG (2015) Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68:438–450CrossRefPubMed
5.
Dias JL, Pina JM, Joao R et al (2015) Multiparametric resonance imaging. Acta Medica Port 28:240–249CrossRef
6.
De Visschere PJ, Briganti A, Fütterer JJ et al (2016) Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging 2:205–214CrossRef
7.
De Visschere PJ, Vral A, Perletti G et al (2017) Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate. Eur Radiol 5:2095–2109CrossRef
8.
Johnson W, Taylor MB, Carrington BM, Bonington SC, Swindell R (2007) The value of hyoscine butylbromide in pelvic MRI. Clin Radiol 62:1087–1093CrossRefPubMed
9.
Park SH, Huh J, Park SH, Lee SS, Kim AY, Yang SK (2016) Diffusion-weighted MR enterography for evaluating Crohn's disease: effect of anti-peristaltic agent on the diagnosis of bowel inflammation. Eur Radiol. doi:10.​1007/​s00330-016-4609-8
10.
Froehlich JM, Daenzer M, von Weymarn C, Erturk SM, Zollikofer CL, Patak MA (2009) Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging. Eur Radiol 19:1387–1393CrossRefPubMed
11.
Marti-Bonmati L, Graells M, Ronchera-Oms CL (1996) Reduction of peristaltic artefacts on magnetic resonance imaging of the abdomen: a comparative evaluation of three drugs. Abdom Imaging 21:309–313CrossRefPubMed
12.
Dosdá R, Martí-Bonmatí L, Ronchera-Oms CL, Mollá E, Arana E (2002) Effect of subcutaneous butylscopolamine administration in the reduction of peristaltic artifacts in 1.5-T MR fast abdominal examinations. Eur Radiol 13:294–298PubMed
13.
Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol 69:16–40CrossRefPubMed
14.
Roethke MC, Kuru TH, Radbruch A, Hadaschik B, Schlemmer HP (2013) Prostate magnetic resonance imaging at 3 Tesla: is administration of hyoscine-N-butyl-bromide mandatory? World J Radiol 5:259–263CrossRefPubMedPubMedCentral
15.
Wagner M, Rief M, Busch J et al (2010) Effect of butylscopolamine on image quality in MRI of the prostate. Clin Radiol 65:460–464CrossRefPubMed
16.
Dyde R, Chapman AH, Gale R, Mackintosh A, Tolan DJ (2008) Precautions to be taken by radiologists and radiographers when prescribing hyoscine-N-butylbromide. Clin Radiol 63:739–743CrossRefPubMed
17.
18.
Schimmöller L, Quentin M, Arsov C et al (2014) MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol 24:2582–2589CrossRefPubMed
19.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Grading Committee ISUP (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed
20.
Shah ZK, Elias SN, Abaza R et al (2015) Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer. Acad Radiol 22:467–474CrossRefPubMedPubMedCentral
21.
Schimmöller L, Blondin D, Arsov C et al (2016) MRI-guided in-bore biopsy: differences between prostate cancer detection and localisation in primary and secondary biopsy settings. AJR Am J Roentgenol 206:92–99CrossRefPubMed
22.
Metadata
Title
Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate
Authors
T. Ullrich
M. Quentin
A. K. Schmaltz
C. Arsov
C. Rubbert
D. Blondin
R. Rabenalt
P. Albers
G. Antoch
L. Schimmöller
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 1/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4940-7

Other articles of this Issue 1/2018

European Radiology 1/2018 Go to the issue

Musculoskeletal

What are the differentiating clinical and MRI-features of enchondromas from low-grade chondrosarcomas?

Oncology

Multi-parametric MRI in cervical cancer: early prediction of response to concurrent chemoradiotherapy in combination with clinical prognostic factors

Neuro

High resolution post-mortem MRI of non-fixed in situ foetal brain in the second trimester of gestation: Normal foetal brain development

Urogenital

MRI of the scrotum: Recommendations of the ESUR Scrotal and Penile Imaging Working Group

Chest

Validation of a model for predicting smear-positive active pulmonary tuberculosis in patients with initial acid-fast bacilli smear-negative sputum

Vascular-Interventional

Primary lower limb lymphoedema: classification with non-contrast MR lymphography